---
title: "CNTX.US (CNTX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CNTX.US/news.md"
symbol: "CNTX.US"
name: "CNTX.US"
parent: "https://longbridge.com/en/quote/CNTX.US.md"
datetime: "2026-05-22T03:23:54.719Z"
locales:
  - [en](https://longbridge.com/en/quote/CNTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CNTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CNTX.US/news.md)
---

# CNTX.US (CNTX.US) — Related News

### [Context Therapeutics Decline Means Insider Profits Down To US$237k](https://longbridge.com/en/news/286911340.md)
*2026-05-19T12:20:42.000Z*
> Context Therapeutics Inc. (NASDAQ:CNTX) insiders have seen their investments yield positive returns despite a recent 10%

### [Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free](https://longbridge.com/en/news/286758291.md)
*2026-05-18T10:53:00.000Z*
> Context Therapeutics has amended its license with BioAtla, agreeing to pay $6.5 million to secure perpetual, royalty-fre

### [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News](https://longbridge.com/en/news/286757134.md)
*2026-05-18T02:45:34.000Z*
> Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

### [What is HC Wainwright's Estimate for CNTX FY2030 Earnings?](https://longbridge.com/en/news/285736759.md)
*2026-05-08T13:46:32.000Z*
> HC Wainwright has revised its FY2030 earnings per share estimate for Context Therapeutics Inc. (NASDAQ:CNTX) from $0.08 

### [Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | CNTX Stock News](https://longbridge.com/en/news/285431403.md)
*2026-05-06T12:18:00.000Z*
> Context Therapeutics Inc. reported its first quarter 2026 financial results, revealing cash and cash equivalents of $54.

### [JonesTrading Remains a Buy on Context Therapeutics (CNTX)](https://longbridge.com/en/news/281799907.md)
*2026-04-06T20:39:25.000Z*
> JonesTrading analyst Soumit Roy has maintained a Buy rating on Context Therapeutics (CNTX) with a price target of $7.00.